NEW YORK, New York — September 4, 2025 — Leads & Copy — IO Biotech (Nasdaq: IOBT) will present at investor conferences, the company announced. Senior management will provide a corporate update and participate in one-on-one meetings at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 and the H.C. Wainwright 27th Annual Global Investment Conference on September 10.
Mai-Britt Zocca, PhD, President and CEO, Amy Sullivan, CFO, and Qasim Ahmad, MD, CMO will present at the Morgan Stanley conference. Zocca will present at the H.C. Wainwright conference. Webcast replays will be available on the company’s website for 90 days.
IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulatory therapeutic cancer vaccines based on its T-win® platform. Its lead candidate, Cylembio®, is currently in Phase 3 trials in combination with Merck’s KEYTRUDA® for advanced melanoma.
Maryann Cimino, Director of Investor Relations, can be reached at 617-710-7305 or mci@iobiotech.com.
Source: IO Biotech
